# Efficacy and Safety of 186 mcg of OPN-375 Nasal Spray Twice a Day (BID) in Adolescents With Chronic Rhinosinusitis Without Nasal Polyps

> **NCT06850805** · PHASE3 · RECRUITING · sponsor: **Optinose US Inc.** · enrollment: 84 (estimated)

## Conditions studied

- Chronic Rhinosinusitis Without Nasal Polyps

## Interventions

- **DRUG:** OPN-375
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06850805
- **Lead sponsor:** Optinose US Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-28
- **Primary completion:** 2028-03-31
- **Final completion:** 2028-10-31
- **Target enrollment:** 84 (ESTIMATED)
- **Last updated:** 2026-03-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06850805

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06850805, "Efficacy and Safety of 186 mcg of OPN-375 Nasal Spray Twice a Day (BID) in Adolescents With Chronic Rhinosinusitis Without Nasal Polyps". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT06850805. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*